| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911486 | Lung Cancer | 2012 | 6 Pages |
Abstract
Our analysis suggests that erlotinib may be an effective and cost-effective third-line treatment for advanced NSCLC compared to best supportive care.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ian Cromwell, Kimberly van der Hoek, Suzanne C. Malfair Taylor, Barbara Melosky, Stuart Peacock,